Key result
Cell-penetrating peptides, particularly LAH4, significantly enhanced the transduction efficiency of AAV9 in the central nervous system in vitro and in vivo after systemic administration.
Why the study?
Applications of recombinant AAV vectors for treating central nervous system diseases are limited by the challenge of effectively delivering them through the blood-brain barrier.
Cell-penetrating peptides like LAH4 can enhance the ability of AAV9 vectors to cross the blood-brain barrier, potentially improving gene therapy delivery for CNS diseases.
Hypothesis-generating for peptide-enhanced AAV vectors; does not support clinical translation of LAH4-AAV9.
Recombinant adeno-associated viruses (rAAVs) have been widely used in the gene therapy field for decades. However, because of the challenge of effectively delivering rAAV vectors through the blood-brain barrier (BBB), their applications for treatment of central nervous system (CNS) diseases are quite limited. In this study, we found that several cell-penetrating peptides (CPPs) can significantly enhance the in vitro transduction efficiency of AAV serotype 9 (AAV9), a promising AAV vector for treatment of CNS diseases, the best of which was the LAH4 peptide. The enhancement of AAV9 transduction by LAH4 relied on binding of the AAV9 capsid to the peptide. Furthermore, we demonstrated that the LAH4 peptide increased the AAV9 transduction in the CNS in vitro and in vivo after systemic administration. Taken together, our results suggest that CPP peptides can interact directly with AAV9 and increase the ability of this AAV vector to cross the BBB, which further induces higher expression of target genes in the brain. Our study will help to improve the applications of AAV gene delivery vectors for the treatment of CNS diseases.
No takes yet. Share an insight, caveat, or question.
Meng et al. (2021) studied Central nervous system (CNS) diseases. Cell-penetrating peptides (LAH4) with AAV9 was evaluated on AAV9 transduction efficiency in the CNS. Cell-penetrating peptides, particularly LAH4, significantly enhanced the transduction efficiency of AAV9 in the central nervous system in vitro and in vivo after systemic administration.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: